Osimertinib is the only third-generation EGFR tyrosine kinase inhibitors clinically approved for first-line treatment of advanced NSCLC patients harboring EGFR mutations. However, drug resistance ...

Head-to-head comparison data versus osimertinib showed Rybrevant plus Lazcluze significantly extended OS in the first-line treatment of patients with locally advanced or metastatic non-small cell ...

Patients with EGFR-mutated NSCLC who received osimertinib had an elevated risk for therapy-related cardiac events. Cardiac events were independently associated with survival. Patients with EGFR ...

Adding a mutation-specific targeted drug to osimertinib (Tagrisso) substantially increased the objective response rate (ORR) in newly diagnosed EGFR-mutant, MET-aberrant non-small cell lung cancer ...

The European Commission has approved Tagrisso (osimertinib; AstraZeneca) combined with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced ...

Results showed treatment with osimertinib reduced the risk of disease progression or death by 84% compared with placebo. The Food and Drug Administration (FDA) has granted Priority Review to the ...

CHICAGO — Osimertinib (Tagrisso) may soon have approvals across all stages of epidermal growth factor receptor (EGFR)–mutated non–small cell lung cancer (NSCLC). The third-generation EGFR ...

Besides the new approval, AstraZeneca released preliminary results for LAURA evaluating osimertinib after chemoradiotherapy. FDA has approved the targeted therapy osimertinib (Tagrisso ...

For patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), osimertinib with chemotherapy leads to significantly longer progression-free survival (PFS) compared with osimertinib ...

Credit: Getty Images. Osimertinib, a kinase inhibitor, is currently marketed under the brand name Tagrisso. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental ...